AU2006203342A1 - New crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Google Patents
New crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it Download PDFInfo
- Publication number
- AU2006203342A1 AU2006203342A1 AU2006203342A AU2006203342A AU2006203342A1 AU 2006203342 A1 AU2006203342 A1 AU 2006203342A1 AU 2006203342 A AU2006203342 A AU 2006203342A AU 2006203342 A AU2006203342 A AU 2006203342A AU 2006203342 A1 AU2006203342 A1 AU 2006203342A1
- Authority
- AU
- Australia
- Prior art keywords
- disorders
- crystalline form
- agomelatine
- formula
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims description 27
- 229960002629 agomelatine Drugs 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 8
- 206010022437 insomnia Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 208000027559 Appetite disease Diseases 0.000 claims description 5
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000012672 seasonal affective disease Diseases 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 238000010586 diagram Methods 0.000 claims description 4
- 210000002249 digestive system Anatomy 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010033664 Panic attack Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 201000003995 melancholia Diseases 0.000 claims description 3
- 230000006984 memory degeneration Effects 0.000 claims description 3
- 208000023060 memory loss Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 3
- 230000035882 stress Effects 0.000 claims description 3
- 230000001193 melatoninergic effect Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- -1 methoxy-l-naphthyl Chemical group 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Description
P001 Section 29 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: New crystalline form of agomelatine, a process for its preparation and pharmaceutical compositions containing it The following statement is a full description of this invention, including the best method of performing it known to us: -1- The present invention relates to a new crystalline form V of agomelatine, or methoxy-l-naphthyl)ethyl]acetamide, of formula NHCOMe MeO
S(I)
a process for its preparation and pharmaceutical compositions containing it.
Agomelatine, or N-[2-(7-methoxy-l-naphthyl)ethyl]acetamide, has valuable pharmacological properties.
Indeed it has the double feature of being, on the one hand, an agonist of melatoninergic system receptors and, on the other hand, an antagonist of the 5-HT 2 c receptor. Those properties confer activity in the central nervous system and, more especially, in the treatment of severe depression, seasonal affective disorders, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue resulting from jetlag, appetite disorders and obesity.
Agomelatine, its preparation and its therapeutic use have been described in European Patent Specification EP 0 447 285.
In view of the pharmaceutical value of this compound, it has been important to be able to obtain it with excellent purity, with well defined crystalline form, perfectly reproducible, which as a result exhibits valuable characteristics in terms of dissolution and formulation and sufficiently stable to allow its storage for long periods without particular requirements for temperature, light, humidity or oxygen level.
Patent Specification EP 0 447 285 describes the preparation of agomelatine in eight steps, starting from 7-methoxy-l-tetralone. However, that document does not specify the conditions for obtaining agomelatine in a form that exhibits those characteristics in a reproducible manner.
The Applicant has now developed a new synthesis process that allows agomelatine to be obtained in a well defined, perfectly reproducible crystalline form that especially exhibits valuable characteristics for dissolution and formulation.
More specifically, the present invention relates to the crystalline form V of the compound of formula characterised by the following powder X-ray diffraction diagram, measured using a Siemens D5005 diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg's angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense ray) 2-Theta d Intensit6 exp. exp. 9.84 8.979 17 12.40 7.134 13.31 6.646 19 15.14 5.848 18 15.98 5.543 18 16.62 5.329 19 17.95 4.939 100 18.88 4.697 20.49 4.332 24 20.99 4.228 34 23.07 3.852 39 23.44 3.792 36 24.28 3.663 58 25.10 3.545 19 26.02 3.422 26.82 3.322 19 27.51 3.239 16 The invention relates also to a process for the preparation of the crystalline form V of the compound of formula which process is characterised in that agomelatine is subjected to a mechanical grinding which is said to be "of high energy".
In the crystallisation process according to the invention it is possible to use the compound of formula obtained by any process.
The invention relates also to another process for the preparation of the crystalline form V of the compound of formula which process is characterised in that agomelatine is heated until complete melting, then immediately put at room temperature and simultaneously a small quantity of crystalline form V of compound of formula freshly prepared is added, and the mixture is cooled until crystallisation is complete.
Preferably, in that second crystallisation process according to the invention, agomelatine will be melted at 110 0
C.
The amount of crystalline form V added in that second process according to the invention will be preferably contained between 1/100 and 1/50 of agomelatine weight.
In that second crystallisation process according to the invention, it is possible to use the compound of formula obtained by any process.
An advantage of obtaining that crystalline form is that it allows the preparation of pharmaceutical formulations having a consistent and reproducible composition, which as a result exhibits valuable characteristics in terms of dissolution which is especially advantageous when the formulations are to be used for oral administration.
A pharmacological study of the form V so obtained has demonstrated that it has substantial activity in respect of the central nervous system and in respect of microcirculation, enabling it to be established that the crystalline form V of agomelatine is useful in the treatment of stress, sleep disorders, anxiety, severe depression, seasonal affective disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, pain, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, and in cerebral circulation disorders. In another field of activity, it appears that the crystalline V form of agomelatine can be used in the treatment of sexual dysfunction, that it has ovulation-inhibiting and immunomodulating properties and that it lends itself to use in the treatment of cancers.
The crystalline form V of agomelatine will preferably be used in the treatment of severe depression, seasonal affective disorders, sleep disorders, cardiovascular pathologies, insomnia and fatigue due to jetlag, appetite disorders and obesity.
The invention relates also to pharmaceutical compositions comprising as active ingredient the crystalline form V of agomelatine together with one or more appropriate inert, nontoxic excipients. Among the pharmaceutical compositions according to the invention there may be mentioned, more especially, those which are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or drag6es, granules, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions and disintegrable pastes.
The useful dosage can be adapted according to the nature and the severity of the disorder, the administration route and the age and weight of the patient. The dosage varies from 0.1 mg to 1 g per day in one or more administrations.
The Examples below illustrate the invention but do not limit it in any way.
Example 1 Crystalline form V of N-[2-(7-Methoxy-l-naphthyl)ethyl]acetamide 100 g of N-[2-(7-Methoxy-l-naphthyl)ethyl]acetamide are put in a mechanical grinder of the vario-planetary mill type for about 6 hours and the solid obtained is characterised by the following powder X-ray diffraction diagram, measured using a Siemens D5005 diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg's angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense ray) 2-Theta d Intensit6 exp. exp. 9.84 8.979 17 12.40 7.134 13.31 6.646 19 15.14 5.848 18 15.98 5.543 18 16.62 5.329 19 17.95 4.939 100 18.88 4.697 20.49 4.332 24 20.99 4.228 34 23.07 3.852 39 23.44 3.792 36 24.28 3.663 58 25.10 3.545 19 26.02 3.422 26.82 3.322 19 27.51 3.239 16 Example 2 Crystalline form V of N-[2-(7-Methoxy-l-naphthyl)ethyllacetamide 4 g of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide are put in a ventilated incubator at 110 0
C.
After 1 hour at 110 0 C, the product is immediately placed at room temperature and seeded with 0.05 g of crystalline form V of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide structurally pure obtained by mechanical grinding of high energy. After 5 minutes, the crystallisation is complete and the solid obtained is characterised by the following powder X-ray diffraction diagram, measured using a Siemens D5005 diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg's angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense ray) Example 3 Pharmaceutical composition Formulation for the preparation of 1000 tablets each containing a dose of 25 mg: Compound of Example 1 or 25 g Lactose 62 g Magnesium 1.3 g Maize 26 g Maltodextrines 9 g Silica, colloidal 0.3 g Sodium starch glycolate type 4 g Stearic acid 2.6 g Example 4 Pharmaceutical composition Formulation for the preparation of 1000 tablets each containing a dose of 25 mg Compound of Example 1 or 2 25 g L actose m 62 g M agnesium stearate 13 g Povidone 9 g Silica, colloidal anhydrous 0.3 g Sodium cellulose glycolate 30 g S tearic acid 2 .6 g Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (15)
1. Crystalline form V of agomelatine of formula MeO. characterised by the following powder X-ray diffraction diagram, measured using a diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg's angle 2 theta, intensity and relative intensity (expressed as a percentage with respect to the most intense ray)
2-Theta d Intensit6 exp. exp.
9.84 8.979 17
12.40 7.134
13.31 6.646 19
15.14 5.848 18 15.98 5.543 18
16.62 5.329 19
17.95 4.939 100
18.88 4.697
20.49 4.332 24 20.99 4.228 34
23.07 3.852 39 23.44 3.792 36
24.28 3.663 58
25.10 3.545 19
26.02 3.422 26.82 3.322 19
27.51 3.239 16 2. Process for the preparation of the crystalline form V of the compound of formula (I) according to claim 1, characterised in that agomelatine is subjected to a mechanical grinding which is said to be "of high energy". 3. Process for the preparation of the crystalline form V of the compound of formula (I) according to claim 1, characterised in that agomelatine is heated until complete melting, then immediately put at room temperature and simultaneously a small quantity of crystalline form V of compound of formula freshly prepared is added, and the mixture is cooled until crystallisation is complete. 4. Pharmaceutical compositions comprising as active ingredient crystalline form V of agomelatine according to claim 1, in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. Pharmaceutical compositions according to claim 4 for use in the manufacture of a medicament for the treatment ofmelatoninergic disorders. 6. Pharmaceutical compositions according to claim 4 for use in the manufacture of a medicament for the treatment of sleep disorders, stress, anxiety, seasonal affective disorders or severe depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, and also in sexual dysfunction, as ovulation inhibitors, immunomodulators and cancers. 7. A method for the treatment of melatoninergic disorders comprising administering to a patient requiring such treatment an effective amount of the crystalline form V of the compound of formula I according to claim 1. 8. A method for the treatment of sleep disorders, stress, anxiety, seasonal affective disorders or severe depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, and also in sexual dysfunction, as ovulation inhibitors, immunomodulators and cancers comprising administering to a patient requiring such treatment an effective amount of the crystalline form V of the compound of formula according to claim 1. 9. A crystalline form V of agomelatine of formula as described herein with reference to examples 1 and 2. A pharmaceutical composition comprising as active ingredient crystalline form V of agomelatine as hereinbefore described with reference to examples 3 and 4. DATED this 3rd day of August 2006 LES LABORATOIRES SERVIER WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P27455AU00 CJH/MEH
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0508278A FR2889523B1 (en) | 2005-08-03 | 2005-08-03 | NOVEL CRYSTALLINE FORM V OF AGOMELATIN, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR05.08278 | 2005-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2006203342A1 true AU2006203342A1 (en) | 2007-02-22 |
AU2006203342B2 AU2006203342B2 (en) | 2012-07-19 |
Family
ID=36581629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006203342A Ceased AU2006203342B2 (en) | 2005-08-03 | 2006-08-03 | New crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
Country Status (38)
Country | Link |
---|---|
EP (2) | EP1752443B1 (en) |
JP (1) | JP4575337B2 (en) |
CN (1) | CN100448843C (en) |
AP (1) | AP2486A (en) |
AR (1) | AR057715A1 (en) |
AU (1) | AU2006203342B2 (en) |
BR (1) | BRPI0603059A (en) |
CA (1) | CA2555115C (en) |
CR (1) | CR8529A (en) |
CU (1) | CU20060153A7 (en) |
CY (1) | CY1113011T1 (en) |
DK (1) | DK1752443T3 (en) |
EA (1) | EA011030B1 (en) |
EC (1) | ECSP066715A (en) |
ES (1) | ES2391406T3 (en) |
FR (1) | FR2889523B1 (en) |
GT (1) | GT200600346A (en) |
HK (1) | HK1098128A1 (en) |
HR (1) | HRP20120779T1 (en) |
IL (1) | IL177173A (en) |
JO (1) | JO2793B1 (en) |
MA (1) | MA28451B1 (en) |
ME (1) | ME02026B (en) |
MX (1) | MXPA06008789A (en) |
MY (1) | MY139902A (en) |
NO (1) | NO336967B1 (en) |
NZ (1) | NZ548864A (en) |
PE (1) | PE20070365A1 (en) |
PL (1) | PL1752443T3 (en) |
PT (1) | PT1752443E (en) |
RS (1) | RS52423B (en) |
SA (1) | SA06270255B1 (en) |
SG (1) | SG130110A1 (en) |
SI (1) | SI1752443T1 (en) |
TW (1) | TWI359128B (en) |
UA (1) | UA83720C2 (en) |
WO (1) | WO2007015004A2 (en) |
ZA (1) | ZA200606453B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2934856B1 (en) * | 2008-08-05 | 2010-08-13 | Servier Lab | NEW PROCESS FOR OBTAINING THE V-CRYSTALLINE FORM OF AGOMELATIN |
CN101481321B (en) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | Agomelatine halogen hydride complex and preparation thereof |
CN101585779B (en) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | New crystal form of Agomelatine, preparation method and use thereof |
WO2011006387A1 (en) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | Process for preparing agomelatine, crystals of agomelatine and preparing process thereof |
CN102001959B (en) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | Medicinal crystal as well as preparation method and application thereof |
CN102050755B (en) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms |
CN101781226B (en) * | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | Agomelatine and medicine composition thereof |
CL2011001405A1 (en) | 2010-06-10 | 2012-03-30 | Gador S A Conicet | Procedure for the preparation of n- [2- (7-methoxy-1-naphthyl) ethyl] acetamide, agomethalin. |
CN102000583B (en) * | 2010-11-18 | 2012-08-15 | 烟台万华聚氨酯股份有限公司 | Catalyst for preparing chlorine by oxidizing hydrogen chloride and preparation method thereof |
CN102690209A (en) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | Mixed crystal of agomelatine (form-VIII), preparation method and application thereof and pharmaceutical composition containing the same |
CN102690210A (en) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | Novel crystal form VII of agomelatine, preparation method and application thereof and pharmaceutical composition containing the same |
CA3209613A1 (en) * | 2011-06-02 | 2012-12-06 | CHINOIN Zrt. | Novel processes for the preparation of prostaglandin amides |
FR2978916B1 (en) | 2011-08-10 | 2013-07-26 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
EP2771312B1 (en) | 2011-11-30 | 2017-05-31 | ratiopharm GmbH | Agomelatine-urea complex and crystalline forms thereof |
CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
CN103360275B (en) * | 2012-03-30 | 2015-04-22 | 上海创诺制药有限公司 | Method for preparing agomelatine I-type crystal |
WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
FR3001894A1 (en) | 2013-02-08 | 2014-08-15 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
PL2810656T3 (en) | 2013-06-06 | 2018-01-31 | Zentiva Ks | Agomelatine formulations comprising agomelatine in the form of co-crystals |
EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
CZ2013621A3 (en) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Agomelatine thermodynamically stable congealed solution for use in pharmaceutical formulation |
WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
FR3033131B1 (en) | 2015-02-26 | 2017-11-17 | Servitronique | SLIDE FOR ITS SLIDING ADJUSTMENT SYSTEMS AND ASSEMBLY METHOD |
ES2959460T3 (en) | 2015-03-31 | 2024-02-26 | Fis Fabbrica Italiana Sintetici Spa | solid form of agomelatine |
EP3466413A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
EP3466923A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Process for the preparation of agomelatine in crystalline form |
CN113952323A (en) * | 2021-12-10 | 2022-01-21 | 李甜 | Application of agomelatine in inhibition of Ube2c protein expression |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (en) * | 1990-02-27 | 1993-12-31 | Adir Cie | NOVEL DERIVATIVES WITH NAPHTHALENIC STRUCTURE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2866336B1 (en) * | 2004-02-13 | 2006-03-24 | Servier Lab | NOVEL PROCESS FOR THE SYNTHESIS OF (7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL) ACETONITRILE AND APPLICATION TO THE SYNTHESIS OF AGOMELATIN |
FR2866335B1 (en) * | 2004-02-13 | 2006-05-26 | Servier Lab | NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN |
-
2005
- 2005-08-03 FR FR0508278A patent/FR2889523B1/en not_active Expired - Fee Related
-
2006
- 2006-07-19 PE PE2006000868A patent/PE20070365A1/en not_active Application Discontinuation
- 2006-07-20 EC EC2006006715A patent/ECSP066715A/es unknown
- 2006-07-24 AP AP2006003695A patent/AP2486A/en active
- 2006-07-24 MA MA29212A patent/MA28451B1/en unknown
- 2006-07-24 CR CR8529A patent/CR8529A/en unknown
- 2006-07-24 JO JO2006247A patent/JO2793B1/en active
- 2006-07-31 GT GT200600346A patent/GT200600346A/en unknown
- 2006-07-31 IL IL177173A patent/IL177173A/en active IP Right Grant
- 2006-08-01 SA SA06270255A patent/SA06270255B1/en unknown
- 2006-08-01 SG SG200605171-8A patent/SG130110A1/en unknown
- 2006-08-01 NZ NZ548864A patent/NZ548864A/en unknown
- 2006-08-02 WO PCT/FR2006/001869 patent/WO2007015004A2/en active Application Filing
- 2006-08-02 ES ES06291251T patent/ES2391406T3/en active Active
- 2006-08-02 TW TW095128302A patent/TWI359128B/en not_active IP Right Cessation
- 2006-08-02 EP EP06291251A patent/EP1752443B1/en active Active
- 2006-08-02 RS RS20120327A patent/RS52423B/en unknown
- 2006-08-02 MY MYPI20063736A patent/MY139902A/en unknown
- 2006-08-02 PL PL06291251T patent/PL1752443T3/en unknown
- 2006-08-02 UA UAA200608689A patent/UA83720C2/en unknown
- 2006-08-02 SI SI200631396T patent/SI1752443T1/en unknown
- 2006-08-02 DK DK06291251.4T patent/DK1752443T3/en active
- 2006-08-02 NO NO20063517A patent/NO336967B1/en unknown
- 2006-08-02 CU CU20060153A patent/CU20060153A7/en unknown
- 2006-08-02 EP EP10011469A patent/EP2277857A3/en not_active Withdrawn
- 2006-08-02 AR ARP060103366A patent/AR057715A1/en not_active Application Discontinuation
- 2006-08-02 BR BRPI0603059-9A patent/BRPI0603059A/en not_active Application Discontinuation
- 2006-08-02 ME MEP-2012-327A patent/ME02026B/en unknown
- 2006-08-02 PT PT06291251T patent/PT1752443E/en unknown
- 2006-08-02 EA EA200601273A patent/EA011030B1/en unknown
- 2006-08-03 ZA ZA200606453A patent/ZA200606453B/en unknown
- 2006-08-03 CN CNB2006101083952A patent/CN100448843C/en active Active
- 2006-08-03 CA CA2555115A patent/CA2555115C/en active Active
- 2006-08-03 JP JP2006211622A patent/JP4575337B2/en active Active
- 2006-08-03 AU AU2006203342A patent/AU2006203342B2/en not_active Ceased
- 2006-08-03 MX MXPA06008789A patent/MXPA06008789A/en active IP Right Grant
-
2007
- 2007-04-30 HK HK07104583.8A patent/HK1098128A1/en not_active IP Right Cessation
-
2012
- 2012-07-18 CY CY20121100635T patent/CY1113011T1/en unknown
- 2012-10-01 HR HRP20120779TT patent/HRP20120779T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006203342B2 (en) | New crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
AU2006203340B2 (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
AU2006203336B2 (en) | New crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
AU2008243132B2 (en) | New crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
US7358395B2 (en) | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
US7939566B2 (en) | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
US7910625B2 (en) | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
KR100904116B1 (en) | New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
KR20070017019A (en) | New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
KR20070017020A (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |